Malaria transmission occurs year-round in Cameroon and is most intense in the south of the country. The annual reported number of malaria cases in 2021 was 3,420,788 with 3,782 deaths.
Malaria
Global Fund Update
The Global Fund has announced that Cameroon will receive US$288 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Cameroon's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Cameroon this is calculated at US$109.7 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Cameroon is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress
The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard Cameroon secured the resources to cover the costs of the LLINs, ACTs and RDTs needed in 2022. Cameroon has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO and has completed the insecticide resistance monitoring and management plan. and has carried out drug resistance testing since 2018 and has reported the results to WHO. The national strategic plan includes activities targeting refugees and IDPs. The country is also showing leadership in malaria control through its participation in the High Burden High Impact approach and has launched the Zero Malaria Starts with me campaign.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Cameroon has enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Control Scorecard. The country is also planning the launch of the End Malaria Council and Fund.

Impact
The annual reported number of malaria cases in 2021 was 3,420,788 with 3,782 deaths.

Key Challenges
- Insecticide resistance.
- Delays in the completion of the universal coverage campaign.
- Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases.
### Previous Key Recommended Action

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact</td>
<td>Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic</td>
<td>Q4 2022</td>
<td>The country completed the ITN mass distribution in the central region. The SMC campaign targeting children under five years was completed. The NMCP is implementing the MPR which will lead to the development of the new MSP. The NMCP is under finalization of the 2022 MIS data collection</td>
<td></td>
</tr>
</tbody>
</table>

### RMNCAH and NTDs

**Progress**

Cameroon has achieved good coverage in the tracer RMNCAH intervention, Vitamin A.

Progress in addressing Neglected Tropical Diseases (NTDs) in Cameroon is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. Preventive chemotherapy coverage in Cameroon is low for lymphatic filariasis (34%) and for trachoma (72%). It is good for onchocerchiasi (70%), soil transmitted helminthiasis (75%) and high for schistosomiasis (97%). Overall, the NTD preventive chemotherapy coverage index for Cameroon in 2021 is 66 and this represents substantial increase compared with the 2020 index value (4).

### Previous Key Recommended Actions

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
<th>Progress</th>
<th>Comments - key activities/accomplishments since last quarterly report</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMNCAH(^1): Impact</td>
<td>Ensure that essential RMNCAH services are sustained and implemented whilst using COVID-19 sensitive guidelines</td>
<td>Q4 2022</td>
<td>No progress reported</td>
<td></td>
</tr>
<tr>
<td>NTDs</td>
<td>Recognising the negative impact of COVID-19 on the 2020 MDA coverage, ensure that NTD interventions are implemented whilst using Covid-19 sensitive guidelines during the pandemic</td>
<td>Q4 2022</td>
<td>The country has been conducting NTD prevention and control activities whilst respecting COVID-19 measures. In Q4 2022, the country organized a Mass Deworming campaign in 8 regions (out of 10 targeted) and the country is working on the report. Other routine activities including guinea worm surveillance and coordination meetings were conducted</td>
<td></td>
</tr>
<tr>
<td>Optimise quality of care</td>
<td>Address falling coverage of vitamin A</td>
<td>Q4 2022</td>
<td>The country significantly increased the coverage of vitamin A in 2021 to 85%</td>
<td></td>
</tr>
</tbody>
</table>

The country has responded positively to previous recommended action on accelerating coverage of ARTs in children under 14 years of age, with a 2% increase reported in the last year.

---

\(^1\) RMNCAH metrics, recommended actions and response tracked through WHO
### New Key Recommended Action

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action Item</th>
<th>Suggested completion timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTDs</td>
<td>Work to increase the preventive chemotherapy coverage for lymphatic filariasis and trachoma and reach WHO targets. Ensure that NTD interventions are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catch-up activities as well as conducting stock reconciliation following a national and subnational physical inventory count tracking of leftover stocks at district level and retrieving all expired drugs after MDA for incineration and accountability</td>
<td>Q4 2023</td>
</tr>
</tbody>
</table>

**Key**
- Green: Action achieved
- Yellow: Some progress
- Red: No progress
- Gray: Deliverable not yet due